• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Medical Announces New Appointments to Board of Directors

    1/5/22 4:05:00 PM ET
    $JNJ
    $ORCL
    $PHG
    $TCMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $JNJ alert in real time by email

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will be retiring from the Board ahead of the May shareholder meeting: Peter Soderberg, Richard Nigon and Kevin Roche.

    "We are extremely pleased to welcome Valerie and Brent to our Board; both experienced leaders, adding depth of expertise in the treatment of chronically ill patients and channels to access and support them," said Bill Burke, Chairman of the Board of Tactile Medical. "I would also like to extend my sincere gratitude to Peter, Dick and Kevin for their dedicated years of service. Their counsel and oversight played an important role in helping Tactile Medical become a successful company, eclipsing $200 million in annual revenue."

    Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. Ms. Asbury previously held a series of leadership roles within Johnson & Johnson (NYSE:JNJ) for over 20 years from 1998 to 2018, including executive sales and general management positions. Her most recent position at Johnson & Johnson was Global President of Diabetes Solutions from 2013 to 2018, including the Global LifeScan subsidiary until its sale in October 2018 to Platinum Equity, a leading private investment firm. She holds a Bachelor of Science in Nursing from Vanderbilt University.

    Brent Shafer most recently served as Chairman and CEO of Cerner Corporation from 2018 until September 2021, a global healthcare technology company that was acquired by Oracle Corporation (NYSE:ORCL) in December 2021. Prior to Cerner, Mr. Shafer was Chief Executive Officer of Philips North America, a health technology company and the North American division of Koninklijke Philips N.V. (("Philips", NYSE:PHG, AEX: PHIA)), from 2014 to 2018. Mr. Shafer also served as Chief Executive Officer of the global Philips' Home Healthcare Solutions business from 2010 until 2014. Mr. Shafer previously held a series of leadership roles at Philips, Hill Rom and GE Healthcare. He holds a Bachelor of Science from the University of Utah.

    About Tactile Medical

    Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.  



    Investor Inquiries:
    Mike Piccinino, CFA
    Managing Director
    ICR Westwicke
    [email protected]

    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $ORCL
    $PHG
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Oracle Corporation
    $ORCL
    10/13/2025$345.00 → $355.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    10/9/2025$365.00Outperform
    Robert W. Baird
    Tactile Systems Technology Inc.
    $TCMD
    10/3/2025$23.50Buy
    Lake Street
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Oracle Corporation
    $ORCL
    9/25/2025$175.00Sell
    Rothschild & Co Redburn
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Oracle Corporation
    $ORCL
    9/10/2025$410.00Neutral → Buy
    Citigroup
    More analyst ratings

    $JNJ
    $ORCL
    $PHG
    $TCMD
    SEC Filings

    View All

    SEC Form 144 filed by Oracle Corporation

    144 - ORACLE CORP (0001341439) (Subject)

    10/23/25 12:50:58 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Johnson & Johnson

    10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

    10/22/25 4:04:17 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    10/14/25 7:22:58 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

    In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study 67% of patients treated with icotrokinra achieved overall rates of clear or almost clear skin by Week 24, which was maintained through Week 52 Icotrokinra continues to show potential with its standout combination of exceptional skin clearance and favorable safety profile in a once daily pill SPRING HOUSE, Pa., Oct. 24, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class

    10/24/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enterprises Rapidly Adopt Oracle Payments, Powered by Adyen, to offer Seamless Customer Experiences

    From the field to the front desk, Oracle Payments delivers a connected, cohesive embedded payments platform for restaurant, sports & entertainment, hospitality, and healthcare organizations AUSTIN, Texas and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Global enterprises continue to trust their embedded finance needs to Oracle Payments, powered by Oracle partner Adyen. Today, more than 2,550 organizations with over 16,200 venues are benefitting from the security, performance, and ease of the integrated, enterprise-grade payments solution. This includes hospitality, restaurant, healthcare, and sports and entertainment operations across the US and UK.

    10/23/25 9:06:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20251022905443/en/ Media contact: [email protected] Investor contact: [email protected]

    10/22/25 4:36:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Oracle with a new price target

    BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $355.00 from $345.00 previously

    10/13/25 8:34:17 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Robert W. Baird initiated coverage on Oracle with a new price target

    Robert W. Baird initiated coverage of Oracle with a rating of Outperform and set a new price target of $365.00

    10/9/25 8:28:15 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    7/9/25 4:39:51 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    3/21/25 8:43:30 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    2/14/25 4:41:16 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Accounting Officer Smith Maria sold $2,803,122 worth of shares (10,000 units at $280.31), decreasing direct ownership by 18% to 47,083 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    10/23/25 8:51:16 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Magouyrk Clayton M. sold $11,065,508 worth of shares (40,000 units at $276.64), decreasing direct ownership by 21% to 154,030 units (SEC Form 4)

    4 - ORACLE CORP (0001341439) (Issuer)

    10/23/25 8:39:34 PM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    EVP, Innovative Medicine, R&D Reed John C exercised 21,721 shares at a strike of $157.92 and sold $4,185,793 worth of shares (21,721 units at $192.71) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    10/20/25 7:13:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Financials

    Live finance-specific insights

    View All

    Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025

    MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2025 financial results will be released after the market closes on Monday, November 3, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provide

    10/20/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

    10/14/25 6:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

    Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

    10/14/25 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Health Systems Simplify Secure Data Exchange with Oracle Health

    New Oracle Health Connection Hub delivers single, unified console to enable data sharing control, auditing, and governance so health systems can easily manage a broad range of interoperability services Early adopters see 50 percent reduction in processing times of Social Security Administration disability benefit claims AUSTIN, Texas, Oct. 9, 2025 /PRNewswire/ -- Oracle Health Connection Hub is now generally available for U.S. healthcare providers, enabling them to use a single console to more easily onboard, access, and manage preferences for Oracle Health interoperability solutions. The latest step in Oracle's strategy to increase interoperability and reduce friction between payers and pr

    10/9/25 9:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/8/24 3:21:42 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care